Ovid Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $733 | $0 | $718 | $132 |
Gross Profit | 733 | -35 | 718 | 132 |
EBITDA | -15,382 | -17,811 | 9,680 | -12,142 |
EBIT | -15,398 | -17,846 | 9,663 | -12,158 |
Net Income | -15,009 | -16,988 | 9,663 | -12,158 |
Net Change In Cash | 733 | 0 | 718 | 132 |
Free Cash Flow | -17,594 | -13,899 | -10,408 | -12,872 |
Cash | 11,327 | 94,064 | 13,153 | 20,611 |
Basic Shares | 73,735 | 73,735 | 81,671 | 71,109 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $7,252 | $566 | $392 | $1,502 |
Gross Profit | 6,952 | 566 | 392 | 1,502 |
EBITDA | -17,114 | -57,772 | -57,013 | -54,166 |
EBIT | -17,414 | -58,385 | -57,581 | -55,548 |
Net Income | -17,414 | -26,433 | -52,339 | -51,408 |
Net Change In Cash | 7,252 | 566 | 392 | 1,502 |
Cost of Revenue | -142,929 | |||
Free Cash Flow | -38,334 | -56,027 | -45,918 | -56,645 |
Cash | 13,153 | 26,301 | 27,042 | 44,867 |
Basic Shares | 73,735 | 70,905 | 70,581 | 70,425 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.08 |
2026-03-31 | -$0.12 |
2025-12-31 | $0.06 |
2025-09-30 | -$0.17 |